AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03159650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravascular ultrasonography
Description: intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
Study NCT03159650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular ultrasonography
Description: intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
Study NCT03524378 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ergonomic and movement modifications
Description: Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
Study NCT01059851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast
Study NCT00433290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
Study NCT00433290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo every day (QD), by mouth (PO) for 13 weeks
Study NCT00817791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen pretreatment (GR2200)
Description: 2 hours/day,5 days before surgery
Study NCT01895842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1.
Study NCT04905498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial Advertising Literacy Training
Description: Children were shown food commercials and in between those commercials they saw and heard statements such as These foods won't make you happy and Those foods are so unhealthy.
Study NCT04905498 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Children were shown food commercials that were the same length as the other group but did not receive any information about whether the content was truthful.
Study NCT01902771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
Study NCT01902771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate
Description: Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
Study NCT03672162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total abdominal hysterectomy
Description: Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
Study NCT03672162 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Total abdominal hysterectomy
Description: Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
Study NCT00544882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-1021
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
Study NCT00544882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mircette®
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
Study NCT00544882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kariva®
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
Study NCT00541307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
Description: Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
Study NCT00544882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kariva®
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
Study NCT00637897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00637897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Study NCT00637897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01902771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
Study NCT00637897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Study NCT00637897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Study NCT03975998 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve repair
Description: Minimally invasive repair of severe organic mitral regurgiation
Study NCT02970617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Intervention
Description: Ring bell after final radiation treatment
Study NCT02130141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
Study NCT02970617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02970617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02970617 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy with or without chemotherapy
Study NCT02130141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dark chocolate
Description: Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
Study NCT01902771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
Study NCT02130141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counselling
Description: Usual snacks are limited.
Study NCT01653886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast (1-2 hours, in the morning)
Description: You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
Study NCT03040570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative oxygenation target
Description: Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
Study NCT03040570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liberal oxygenation target
Description: Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining >94%.
Study NCT00409175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fx-1006A
Description: Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
Study NCT00409175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
Study NCT02101814 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y gastric bypass (bariatric surgery)
Study NCT02436980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: GROUP T
Study NCT02436980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: GROUP M
Study NCT02777749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
Study NCT01268579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
Study NCT02598336 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Structured Light Plethysmography
Description: Non contact device that uses light to record displacement of the anterior thorax and abdomen region
Study NCT02598336 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pneumotachograph Spirometry
Description: Device that measures airflow at the mouth using a mouthpiece
Study NCT00907660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss counseling
Description: Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
Study NCT00907660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss counseling
Description: Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
Study NCT00907660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Portion-Controlled Foods
Description: Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study.
Study NCT00907660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Portion-Controlled Foods
Description: Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study.
Study NCT02970617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy with or without chemotherapy
Study NCT00432237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974 50 mg
Study NCT00432237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974 150 mg
Study NCT00432237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974 300 mg
Study NCT01653886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lunch (1-2 Hours, at midday)
Description: You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
Study NCT00432237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
Study NCT04013126 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: • Endothelial function using ENDOPAT system
Description: All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
Study NCT04013126 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: • Endothelial function using ENDOPAT system
Description: All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
Study NCT01653886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dinner (1-2 hours, in the afternoon)
Description: You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
Study NCT01271855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belladonna and opioid suppository
Description: Belladonna and opioid suppository 16.2mg/30mg per rectum every 8 hours for 24 hours following delivery
Study NCT01271855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycerin Suppository
Description: A vegetable oil suppository (placebo) per rectum every 8 hours for the first 24 hours following delivery.
Study NCT05206461 — intervention group
Intervention type: OTHER
Intervention: Trunk Control Measurement Scale
Description: Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
Study NCT04000646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: standard care non-pharmacologic interventions during anesthesia induction
Study NCT04000646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breath-controlled app
Description: breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 40 mg/m\^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3.
Study NCT00857389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: 1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (Filgrastim)
Description: 5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
Study NCT00857389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
Study NCT01452347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 1mg
Description: comparator warfarin
Study NCT01452347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate intermediate dose
Description: active treatment (medium)
Study NCT01452347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate low dose
Description: active treatment (low)
Study NCT01452347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 5mg
Description: comparator warfarin
Study NCT01452347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate high dose
Description: active treatment (high)
Study NCT01452347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 3mg
Description: comparator warfarin
Study NCT01537367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced contact plus behavioral skills
Description: The enhanced contact plus behavioral skills arm is the longer experimental arm.
Study NCT01537367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced contact only
Description: The enhanced contact only arm is the shorter experimental arm.
Study NCT01537367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard of care arm is the comparison group arm that receives only standard clinical services.
Study NCT04179630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin (NGM282)
Description: Single 3 mg dose
Study NCT01179399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-960
Description: TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
Study NCT00962767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: 2 IV infusions 6 mg/m2 administered monthly
Study NCT00962767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA plus 6-MP and MTX
Description: 6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
Study NCT01991951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Study NCT01991951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Study NCT03366584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta carotene
Description: Beta carotene 25,000 IU
Study NCT03366584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 50,000 IU
Study NCT03366584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc 50 mg
Study NCT03366584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 6 mg
Study NCT03366584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 6 mg
Study NCT00566033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit-driven intervention
Description: Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
Study NCT03217825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rostafuroxin
Description: This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
Study NCT02988856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic lid system
Description: Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
Study NCT00928811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: basiliximab
Description: Simulect 20 mg intravenously day of transplant and day 4
Study NCT00928811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.